Gilead Sciences, Inc. $GILD Holdings Trimmed by Capital World Investors

Capital World Investors cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 45,179,931 shares of the biopharmaceutical company’s stock after selling 1,123,368 shares during the quarter. Capital World Investors owned 3.64% of Gilead Sciences worth $5,015,469,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. Csenge Advisory Group boosted its stake in Gilead Sciences by 319.0% in the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock valued at $2,375,000 after acquiring an additional 16,288 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in Gilead Sciences by 52.1% during the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after acquiring an additional 26,882 shares in the last quarter. Cookson Peirce & Co. Inc. grew its position in shares of Gilead Sciences by 249.1% in the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after purchasing an additional 7,168 shares during the period. Railway Pension Investments Ltd increased its position in shares of Gilead Sciences by 3.1% during the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after acquiring an additional 42,200 shares in the last quarter. Finally, TriaGen Wealth Management LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at about $1,274,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $144.79, for a total value of $1,447,900.00. Following the transaction, the chief executive officer owned 642,308 shares in the company, valued at approximately $92,999,775.32. The trade was a 1.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the transaction, the insider directly owned 120,288 shares of the company’s stock, valued at $18,577,278.72. This represents a 18.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 309,280 shares of company stock worth $43,935,470. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 1.9%

Shares of NASDAQ GILD opened at $146.63 on Tuesday. The company has a 50 day simple moving average of $138.73 and a 200 day simple moving average of $126.06. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The firm has a market cap of $182.03 billion, a PE ratio of 21.66, a price-to-earnings-growth ratio of 1.89 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, March 13th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is presently 46.68%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Citigroup reiterated a “buy” rating on shares of Gilead Sciences in a research note on Friday. Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Bank of America set a $162.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Wolfe Research upped their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Finally, Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Twenty-three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $156.72.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.